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Abstract
Incomplete spontaneous regression of melanoma is common. However, complete melanoma regression is still a
very rare phenomenon. Because melanoma is the most immunogenic human malignancy, the mechanisms lead-
ing to regression, based on accumulative evidence, are the host’s immune responses. Unfortunately, therapies
aiming to enhance the patient’s natural immunity against melanoma have yet to meet their expectations. Reasons
for failure include various immune escape mechanisms, induced by the tumor, that subsequently lead to tolerance.
Here, we performed time-dependent gene expression profiling to unravel molecular changes involved in the
transition of progressive melanoma to complete tumor regression using a porcine model. The melanoblastoma-
bearing Libechov minipigs are highly suitable for this study because these animals exhibit naturally occurring and
regressing melanomas. We were able to identify a molecular signature of the melanoma regression process.
Genes regulated in this signature were associated with 1) cell cycle, 2) immune response, and 3) melanocyte dif-
ferentiation. These genes may shed light on molecular mechanisms involved in complete melanoma regression
and indicate what improvements are needed for successful antimelanoma therapy.
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Introduction
Complete regression of cancer is the ideal outcome of any antitumor
therapy. At present, no such treatment exists for advanced melanoma
because melanoma cells exhibit an extraordinary resistance to chemo-
therapy, radiotherapy, and even immunotherapy [1]. Hence, its resis-
tivity to treatment and aggressiveness make it the most fatal of all
skin cancers, with mortality of patients with metastasis reaching
>95% within 5 years [2]. Interestingly, total regression of advanced
melanoma occurs spontaneously, where spontaneous regression
refers to the disappearance of the malignant tumor mass without
treatment or as a consequence of an indirect action (i.e., treatment
against another disease or symptoms) [3]. Complete regression of
metastatic melanoma is an extremely rare occurrence with only
38 well-documented cases [4]. However, the regression could be
more common than reported because it is prone to escape detection
[5]. Nevertheless, partial regression is observed more frequently with
7% to 61% in thin melanoma [6]. Clinically, partial regression is
mainly characterized by a heterogeneous pigmentation of the tumor
site. Whereas on a histopathologic level, the process starts with a dense
infiltrate of lymphocytes and ends with fibrosis and/or melanosis
within a thickened papillary dermis [7]. Different mechanisms such
as immune recognition, virus infection of tumor cells, cytokine-
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induced apoptosis, high levels of stress-induced steroids, hypoxic con-
ditions, telomeric breaks, and gene mutations have been discussed as
mediators of regression but clear evidence is missing [8].
The melanoblastoma-bearing Libechov minipigs (MeLiM) have
been described as a suitable animal model to study melanoma and
its regression because the tumors occur and vanish naturally and
melanocytes are localized at the basal layer of the epidermis. In addi-
tion, large litters allow studies of homogenous genetic background.
Spontaneous complete tumor regression occurs in 96% of MeLiM
and is characterized by tumor flattening, tumor drying, depigmenta-
tion, and infiltration of firstly melanophages and then lymphocytes
[9]. The biggest difference between humans and pigs is the early onset
of regression in MeLiM, which occurs during childhood, and its ex-
treme efficiency. The elucidation of regression mechanisms is of valuable
interest to find a more specific therapy to treat the disease. Therefore,
we aimed to study the molecular changes leading to melanoma regres-
sion inMeLiMusing Porcine Genome Arrays (GeneChip, Affymetrix,
High Wyecombe, UK). We have conducted time-dependent gene ex-
pression profiling to characterize transcriptomic changes leading from
melanoma progression to spontaneous regression. We were able to
identify characteristic gene signatures and significant molecular path-
ways associated with spontaneous and complete melanoma regression.
Materials and Methods
Biologic Samples
Time-dependent gene expression profiling of spontaneously regres-
sing melanomas was performed at five different time points, namely,
t0 = day + 8 after birth (d + 8), t1 = d + 28, t2 = d + 49, t3 = d + 70, and
t4 = d + 91. Six MeLiM of the same litter were chosen, which were
homozygous for predisposition quantitative trait loci located on Sus
scrofa chromosome (SSC) 1 and SSC6 to ensure the presence of mul-
tiple lesions with high aggressiveness [10]. Tumors were excised surgi-
cally from MeLiM swines under complete anesthesia.
At t0 and t1, n = 6 tumors, at t2 and t3, n = 5 tumors, and at t4, n =
3 tumors were processed for chip hybridization. Number of excised
tumors (n) is equal to the number of used microarrays. In total, n =
25 microarrays were used. Tumor samples were obtained from N
different animals (Table 1). Due to reduced RNA integrity of tumor
samples at t4, only three tumors passed the microarray quality con-
trols. Ulcerated or necrotic regions of tumor sections were maximally
macrodissected before RNA extraction. Collected tumor samples
were stored in liquid nitrogen for RNA extraction and in 10% buff-
ered formalin for histologic diagnosis. Hematoxylin-stained paraffin-
embedded sections were evaluated histologically according to human
classification and for different criteria namely ulceration, vascularity,
fibrosis, hyperkeratosis, and infiltration by inflammatory cells. Clin-
ically, signs of regression included drying surface, flattening, and
depigmentation of the tumor. Histologically, regression was charac-
terized by an extensive infiltration of melanophages, lymphocytes,
dermal fibrosis, and telangiectasia at the tumor site. All experiments
were performed in accordance with the French law for animal exper-
imentation (Décret: 2001-464 29/05/01). The presented study was
approved by the local ethic committee for animal experimentation
(Comité régional d’éthique Ile de France-Sud, project no. 05-030).
RNA Isolation
Total RNAwas extracted from several 16-μm tumor tissue cryosec-
tions using the PicoPure RNA extraction kit (Arcturus Engineering,
Mountain View, CA). The RNA quality was carefully assessed by cap-
illary electrophoresis using the 2100 BioAnalyzer (Agilent, Massy,
France). The RNA quantity and the 260/230 nm ratio, 260/280 nm
and 405/415 nm (detection of melanin contamination) were deter-
mined by spectrometry using Nanodrop (Thermo Fisher Scientific,
Palaiseau, France).
Target Production and Hybridization
Microarray experiments and part of data analysis were performed by
PartnerChip (Evry, France) following theAffymetrix-recommended pro-
cedure. Target was prepared and hybridized according to the Affymetrix
1-cycle technical protocol as described before [11]. Fluorescent images
were detected in a GeneChip Scanner 3000 (Affymetrix). Expression
data and raw expression data (CEL files) were generated using GCOS
software (Affymetrix). Quality control was assessed based on 3′/5′
ratios of glyceraldehyde 3-phosphate dehydrogenase and β-actin con-
trol probe sets.
Normalization and Statistical Analysis
Normalization and statistical analysis of microarray data have been
performed using R resources, Bioconductor statistical packages (http://
www.bioconductor.org/), and the ArrayAssist software (Stratagene
Europe, Amsterdam, The Netherlands) for the analysis of variance
(ANOVA) and k-means analysis. Raw intensity values were subjected
to a preprocessing step using the GC Robust Multiarray Average al-
gorithm that summarizes and normalizes data into gene expression
values. The log2 scale transformation is integrated into this process,
so output values are then log2-transformed and ready to be used for
t test and one-way ANOVA. The time after birth was considered as a
central parameter for one-way ANOVA. Multiple hypotheses testing
was controlled by applying Benjamini–Hochberg false discovery rate
(FDR) correction. P values of the ANOVA were adjusted using the
Benjamini–Hochberg algorithm (FDR or adjusted P value < .01).
Table 1. Tumor Characteristics of Biologic Samples Used for Microarray Analysis.
Time Point n N RIN Clinical Aspect Histologic Aspect
Tumor Type/Clark Level Characteristics Metastasis % Tumor Cells TILs Hair Follicles Vascularization Regression Fibrosis
t0 = day 8 6 6 7.6–9.2 NM/IV–V Ulcerated nodule – plateau-shaped tumor 0 of 5 60–97 0 of 6 ++ ++ 0 of 6 0 of 6
t1 = day 28 6 6 7.6–8.9 NM/IV–V Bleeding ulcerated exophytic tumor 5 of 6 85–98 0 of 6 + +++ 0 of 6 0 of 6
t2 = day 49 5 5 7.4–8.6 NM/IV–V Dry plateau-shaped – dry exophytic tumor 5 of 5 70–95 3 of 5 + ++ Doubtful 5 of 5 4 of 5
t3 = day 70 5 4 7.3–8.5 UC Gray plateau-shaped, dry exophytic, ulcerated
plateau-shaped tumor
5 of 5 60–80 5 of 5 + ++ 5 of 5 5 of 5
t4 = day 91 3 3 7.1–7.8 UC Gray plateau-shaped tumor 3 of 3 30–60 3 of 3 ++ ++ 3 of 3 3 of 3
N indicates the number of different animals from which tumors were excised; n, number of excised tumors equal to the number of used microarrays; NM, nodular melanoma; RIN, RNA integration
number; TIL, tumor-infiltrating lymphocyte; UC, unclassified.
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For the t tests, P value adjustments were performed individually for
each comparison. Probe sets were defined as differentially expressed
for tn versus t0 time points if the fold change (FC) was bigger than
2 and P value was lower than .05 after unpaired t test. Furthermore,
probe sets also found significant after ANOVA were used for k-means
clustering (k = 6). We used k = 6 clusters because most of the time, the
number of clusters is close to the number of time points. In addition,
we grouped our data by k = 9 clusters. Subsequent functional analysis,
however, showed an “overclustering” of the data, as many genes of the
same biologic function were arranged in different k-means clusters. So,
using k = 6 clusters was an experience-based choice but justified by
following functional analysis. Microarray data were submitted to
ArrayExpress (http://www.ebi.ac.uk/microarray-as/aer/entry): Experi-
ment (E-MEXP-1152).
Reannotation of Porcine Affymetrix Probe Sets
The porcine Affymetrix microarray was poorly annotated with less
than 10% of the immobilized probe sets describing a gene and was
therefore reannotated using the method by Tsai et al. [12]. Using this
strategy, 19,675 (82%) of 24,123 transcripts on the Affymetrix por-
cine microarray could be identified, representing 11,256 unique human
genes. The limit of significant homology with human sequence was set
at e-value < e−10.
Functional Pathway Analysis by Ingenuity
A total of 1411 k-means clustered genes (e-value < e−10) were
analyzed by Ingenuity Pathways Analysis (Ingenuity Systems; http://
www.Ingenuity.com). Swiss Prot identifiers were imported into the In-
genuity Pathway Analysis (IPA) Software. Of these genes, 1396 were
mapped to the Ingenuity database. Cluster 1 with 406 IPA-mapped
genes (IMGs) contained 235 network-eligible genes (NEGs), cluster
2 (280 IMGs) contained 184 NEGs, cluster 3 (with 243 IMGs) con-
tained 178 NEGs, cluster 4 (with 242 IMGs) contained 172 NEGs,
cluster 5 (with 128 IMGs) contained 105 NEGs, and cluster 6 (with
97 IMGs) contained 62 NEGs. The identified genes were mapped to
genetic networks available in the Ingenuity database and were then
ranked by score. The score is the probability that a group of genes
equal to or greater than the number in a network (maximum 35 genes)
could be achieved by chance alone. Furthermore, comparison analysis
of the six gene clusters and the different time points (t1–t4) was per-
formed. Ingenuity pathway analysis mapped the clustered genes for
each time point relative to t0 as follows: t1 = 53 genes (42 NEGs),
t2 = 234 genes (183 NEGs), t3 = 1049 genes (719 NEGs), and t4 =
1256 genes (833 NEGs). After single IPA core analysis for each time
point, IPA comparison was performed to analyze changes in biologic
states over time. Functional pathway analysis over time identified
highly significant biologic classes that changed during the progression
and regression of melanoma. The readout of the comparison analysis
were histograms representing the significance (−log P value) of the
functional association that is dependent on the number of genes in
a class and in biologic relevance. The threshold line that appears in
the bar chart represents a P value of .05. In addition, network anal-
ysis was performed for each time point to identify gene interaction.
Quantitative Real-Time Polymerase Chain
Reaction Validation
To validate differentially expressed genes identified by microarray
analysis, we performed quantitative real-time polymerase chain reac-
tion (qRT-PCR) as previously described [13]. We tested 18 genes in
total (CCNB1, CDC2, BUB1B, BIRC5, KIF11, CKAP2, SCIN,
KLRK1, CCL5, IL15, TVB1, SLC37A2, ATP6V0D2, IGHG1,
TRGV9, MITF-M, PRF1, and MLANA). Eighteen genes were chosen
because we wanted to validate genes of the major gene signatures of
interest (cell cycle and immune response). We chose six genes repre-
sentative for the cell cycle signature (CCNB1, CDC2, BUB1B, BIRC5,
KIF11, and CKAP2) and nine genes for the different facets of the
immune response (SCIN, KLRK1, CCL5, IL15, TVB1, SLC37A2,
ATP6V0D2, IGHG1, and TRGV9). Three additional genes were se-
lected that were of interest but not responsive or present on the micro-
array. PRF1 was represented on the porcine GeneChip with two probe
sets, but both were unresponsive. MITF-M and MLANA were not
present on the porcine microarray (Table W2).
Gene List Comparison
To confront our data with human melanoma expression profiles, we
compared our MeLiM data against three human melanoma expression
studies conducted with melanoma tissue and primary melanoma cell
lines [14–16]. The aim was to identify overlapping genes as an indi-
cator of biologic relationship. To evaluate an eventual gene overlap
with a certain significance, we applied the hypergeometric distribution
test (HDT) [14]. Briefly, the test calculates the probability of obtaining
by chance a number k of annotated genes for a given term among a
data set of size n, knowing that the reference data set contains m such
annotated genes out of N genes. In our case, m was the number of
genes in the target gene list, k was the number of genes in our gene
list, n was the number of overlapping genes between m and k, and
N was the number of all possible genes. Because our porcine micro-
array did not represent an approximate 33K human pan genomic
GeneChip, we corrected m (number of genes in the reference data
set) by subtracting genes that were not immobilized.
Because the HDT calculates the probability of having exactly n
overlaps, we repeated the calculation up to four times by increasing
each time n + 1. Adding up these probabilities and using the cumu-
lative results permitted to state the probability of finding at least n
overlaps. The cumulative results were rounded up to the next order
of magnitude to be more conservative.
Tumor-Infiltrating Lymphocyte Isolation and Flow Cytometry
Single-cell suspension of melanoma tissue was obtained by collage-
nase B (Roche, Meylan, France) treatment. Double staining was per-
formed with mouse anti–swine-CD4 at 1:500 (IgG2a, clone PT90A;
VMRD, Inc, Lisseu, France) and mouse anti–swine-CD8α antibody
at 1:500 (IgG2b, clone PT81B; VMRD, Inc). Primary antibody stain-
ing was revealed by R-phycoerythrin–labeled antimouse IgG2a at
1:500 (Southern Biotech,Montrouge, France) and fluorescein isothio-
cyanate (FITC)–labeled antimouse IgG2b at 1:300 (Southern Bio-
tech). Flow cytometry analysis was performed using a FACSCalibur
(BD Biosciences, Le Pont de Claix, France).
Immunohistochemistry
Cryosections were fixed in 95% ethanol for 10 min. Nonspecific
binding sites were blocked by incubation with goat serum. Melanoma
sections were incubated overnight with mouse anti–swine-CD3 (IgG1
at 1:50, clone PPT3; Santa Cruz Biotechnology, Santa Cruz, CA),
mouse anti–swine-CD8α (IgG2b at 1:400, clone PT81B; VMRD,
Inc), anti–swine SWC3a (IgG2b at 1:200, clone 74-22-15a; BD
Pharmingen, Le Pont de Claix, France). CD3, CD8, and SWC3a
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protein stainings were revealed by Alexa Fluor 555–labeled, goat anti-
mouse IgG1 at 1:500 (Invitrogen, Cergy Pontoise, France), and
FITC–labeled goat antimouse IgG2b at 1:500 (Southern Biotech),
respectively. Negative controls were assessed by replacing the primary
antibodies with the nonimmune goat serum at the same concen-




Tumors at t0 and t1 were exclusively growing melanomas of nodular
type with a Clark level of IV-V, with a tumor area consisting mainly of
homogenously distributed melanoma cells (up to 98%; Table 1). The
first signs of regression appeared at t2 (d + 49) with the occurrence of
tumor-infiltrating lymphocytes (TILs; three of five tumors), fibrosis,
and melanophages. This observation pursued, whereas tumors at t3
and t4 showed clear signs of regression namely extensive infiltration of
melanophages, TILs, dermal fibrosis, and telangiectasia. The change of
the tumor microenvironment during regression was also reflected in the
steady decrease of RNA integrity over time. Whereas the highest RNA
integration number (RIN) at t0 was 9.2, the maximal RIN at t4 was 7.8
(Table 1) due to regression-related phenomenon such as necrosis.
Microarray Analysis and Clustering
After normalization and statistical analysis, 1761 probe sets repre-
senting 1411 unique human genes (e-value < e−10) were regulated
over time and grouped into six clusters according to similar expres-
sion behavior. Cluster 1 (Figure 1A) contained the most genes (409),
whereas clusters 2, 3, and 4 were almost equal in numbers (248, 245,
and 244, respectively). Clusters 5 and 6 harbored fewer genes of 131
and 98, respectively (Table W1). The expression profiles of clusters
2, 3, and 5 indicated a general up-regulation of genes over time, with
cluster 5 showing the strongest up-regulation at t3. Clusters 1, 4, and
6’s profiles showed a down-regulation over time, with cluster 6 mark-
ing a dramatic decrease in gene expression from t3 onward. Only
minor differences were detected between t0 and t1 among the six
clusters. However, at t2, more prominent changes in gene expression
profiles were observed (129 genes significantly up-regulated, and 107
down-regulated) reflecting observed histologic changes. Functional
classes were assigned to gene clusters by IPA. Genes of cluster 6
(Figure 1B) were mainly associated with Hair and Skin Development
and Function (P = 1.36 × 10−14), whereas cluster 5 contained mainly
Immune Response– (P = 3.28 × 10−16) and Cell Death– (P = 1.7 × 10−9)
related genes. Cluster 4 genes were highly associated with Cell Cycle
(P = 9.39 × 10−16) and DNA Replication, Recombination, and Repair
(P = 1.44 × 10−11) functions. Genes of cluster 3 were mainly linked
to Cellular Movement (P = 1.61 × 10−10) and Immune Response (P =
1.62 × 10−7). Clusters 1 and 2, containing most genes, showed only
minor regulatory changes over time, and functional comparison to
the other clusters did not render highly specific gene classes.
Time-Dependent Analysis by IPA
To focus on expressional changes at each time point, functional
interpretation and biologic interaction of the clustered genes were
achieved by IPA. As demonstrated in Figure 2A, highly significant
classes namely Cellular Movement, Cell Cycle, Cell Death, Immune Re-
sponse, DNA Replication, Recombination, and Repair, and Hair and
Skin Development and Function changed remarkably over time. To
discern the change in regulation, we included counts for up- and
down-regulated genes for each time point, as well as their range of
FCs as a measure for their “weight” of regulation. Considering these
criteria, t1 (d + 28) showed only minor transcriptomic changes rela-
tive to t0 (d + 8). However, 18 genes were associated with Cell Death,
of which 12 were up-regulated. In addition, at t1, 8 of 9 genes linked
to Immune Response were up-regulated (∼10-fold) and 4 of 10 genes
linked to Cell Cycle functions were down-regulated (2.5-fold). Inter-
estingly, at t2 (d + 49), a remarkable change occurred in the Cell Cycle
class that contained a total number of 52 genes, of which 38 (∼73%)
were down-regulated with up to approximately seven-fold compared
to t0. DNA Replication, Recombination, and Repair, a related class,
showed the same trend with 86% of the genes down-regulated at
t2. The cell cycle genes affected were mainly cyclin-dependent kinases
(CDC2 and CDC6) and cyclins (CCNA2, CCNB1, and CCNB3), as
shown in Figure 2B, and spindle-associated proteins such as members
of the kinesin family (KIF11). Canonical pathway analysis confirmed
this finding, showing genes for G2/M phase, Checkpoint Regulation
being down-regulated at t2 (Figure W1). Furthermore, 48 of 72 genes
involved in cell death were up-regulated at t2. Evidence for an immune
response onset was suggested by the fact that 29 of 30 immune re-
sponse genes were increased up to ∼40-fold at t2. This immune re-
sponse seemed to be established at t3, with ∼82% of the immune
genes being strongly up-regulated (up to ∼100-fold). There were no less
than six canonical pathway classes demonstrating immune response–
associated signaling (Figure W1). These canonical classes indicated a
complex immune invasion because signaling pathways of chemokines,
leukocyte extravasation, and different immune cells such as T cells,
natural killer (NK) cells, and B cells were augmented. The invasion
of immune cells was mirrored by the up-regulation of ∼70% of the
cellular movement genes up to 28-fold at t3. The phenomenon of de-
pigmentation was clearly reflected on the expression level because 50%
of pigmentation genes classified under Hair and Skin Development and
Function were strongly down-regulated.
Comparison to Human Melanoma Expression Studies
We compared our gene lists to those of different human melanoma
gene expression profiling studies to identify overlapping genes [14–
16]. All groups studied the progression of the disease using either
melanoma tissue [16] or primary melanoma cell lines [14,17]. The
probability of finding common genes between two independent gene
lists by random was calculated using the HDT test [14].
Compared to the 174 known genes associated with metastatic dis-
semination of cutaneous melanoma [16], we found 4 overlapping
genes at t1, 27 at t2 (P < 2.86 × 10
−29), 36 at t3 (P < 9.69 × 10
−21),
and 33 at t4 (P < 1.50 × 10
−15; Table W3). Interestingly, common
genes were all down-regulated in our melanoma regression model,
whereas in humans, they were up-regulated suggesting a shorter sur-
vival. In addition, comparison with signatures of aggressive melanoma
cell lines [15] again showed common genes that are associated with
cell cycle progression, DNA replication and repair, and apoptotic re-
sistance, namely, HELLS, BIRC5, GINS1, NUSAP1, MELK, and
NCAP2 (Table W3). Again, we found inverse regulation of those genes
because they were down-regulated from t2 onward during regression.
Ryu et al. [17] also identified a signature for down-regulated genes in
aggressive melanoma compared to primary human melanocytes har-
boring genes of cell adhesion and differentiation-associated genes.
We found a common decrease of mainly differentiation-associated
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Figure 1. k-Means clustered genes regulated during regression and their biologic interpretation. (A) Gene expression profiles of k-means
clustered genes over time. Left upper panel represents the data as a heat map, whereas upper right panel represents the data in a line
chart. Y-axis represents the log2 FC, whereas the X-axis represents the five consecutive time points when microarray analysis was per-
formed. (B) Functional comparison of k-means gene clusters. Y-axis indicates the significance (−log P value) of the functional associ-
ation that is dependent of the number of genes in a class as well as biologic relevance.
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genes namely KIT, OCA2, TYR, and CITED1 from t3 onward. Hoek
et al. [14] identified 223 cohort-specific genes overexpressed in mela-
noma cell cultures, whereas one cohort (neural crest signature) seemed
to be linked with a high proliferative and weak metastatic potential of
melanoma cells, and the other cohort [transforming growth factor beta
(TGFB) signature] seemed to be associated with a weak proliferative
and high metastatic potential. At t3, we identified 19 common genes
(P < 9.91 × 10−6). Of these 19 genes, 15 were associated with the neu-
ral crest signature, and of these 15, 10 were being down-regulated and
5 were up-regulated (Table W3). The last four common genes associ-
ated with the TGFB signature were up-regulated in our model. At t4,
20 overlapping genes (P < 3.34 × 10−5) were detected, of which 16
were neural crest-related and 4 were TGFB signature-related. Eleven
of the neural crest genes were down-regulated, mostly melanocytic
markers, namely, TYR, CITED1, SILV, and GPR143. Of four TGFB
signature-related genes, three were up-regulated but with low FCs.
Immune Response
Focusing on immune response-related genes revealed distinct signa-
tures that were regulated throughout spontaneous melanoma regression
(Figure 3). A monocyte/macrophage–like signature (Figure 3A) was de-
tected, which reached maximal up-regulation on day 70 (t3). This signa-
ture contained macrophage-specific genes, such as the recently described
sugar transporter SLC37A2 [18], B7 family-related phagocytic receptor
VSIG4, and a negative T cell regulator [19], and genes highly expressed in
osteoclast-like cells such as tartrate-resistant phosphatase (ACP5), tran-
scription factor PU.1 (SPI1), calcitonin receptor (CALCR) [20], the ly-
sosomal ATPase V0 subunit D2 (ATP6V0D2) [21], and integrin beta 3
(ITGB3). Moreover, genes involved in differentiation and multinu-
cleation of osteoclasts (CALCR and ATP6V0D2) were the most up-
regulated at t3. Markers for the monocytic lineage included sialic acid
binding Ig-like lectin 5 (SIGLEC5) [22] and C-type lectin domain
family 5 member (CLEC5A) [23] that were approximately 25-fold up-
regulated at t3 (Figure 3A). Classic activation markers such as CD83 and
CD86 remained stably expressed between t3 and t4 with minor FCs.
VSIG4 and CD74, as well as reactive oxygen species (ROS) production-
related genes such as CYBB and CYP2C9, reached maximal expression
at t4. By immunohistochemical analysis, we confirmed an increase of
tumor-infiltrating monocytes during regression, characterized by SWC3
(SIRPA) expression (Figure 4B).
Furthermore, we detected genes related to a T/NK response and dif-
ferent T-cell receptor chains such as alpha, beta, and gamma (TCA,
TVB1, and TRGV9). Genes of the T/NK signature were slightly up-
regulated at t3 and were highly up-regulated at t4 (d + 91; Figure 3B).
By flow cytometry and immunohistochemical analysis, we con-
firmed an extensive infiltration of T cells at t4 (Figures 4B and 5),
where ∼43% and ∼22% were CD8- and CD4-positive, respectively.
Interestingly, the humoral response signature, containing different
immunoglobulins, was most highly up-regulated in the regression pro-
cess. Immunoglobulin heavy chain (IGHM), kappa variable (IGKV1–
5), and the Ig lambda constant (IGLC1) were increased more than
70-fold at t4 (Figure 3C ). The cytokine gene signature showed, as ex-
pected, late up-regulation of T/NK cell–related cytokines and recep-
tors such as CCL5, IL2RG, IL15, and CCR5 (Figure 3D).
Merge of Clinical, Histologic, and Transcriptomic Data
To summarize the transition from melanoma progression to re-
gression on a clinical, histologic, and transcriptomic level, most char-
acteristic tumor samples and their corresponding top 15 up- and
down-regulated genes (Table W4) per time point were demonstrated
(Figure 4). Clinically, tumors of t1 and t0 were mostly exophytic and
highly vascularized. Histologic analysis revealed highly pigmented
homogenous melanoma cells. t2 showed first infiltrations of highly
pigmented macrophage-like cells and could be therefore considered
as the transitional stage between progression and regression. Fibrosis
and drying were also detected. Most up-regulated genes at t2 were
associated with a monocyte/macrophage–like signature (ATP6V0D2,
SLC37A2, CALCR, FN1, ACP5, SPI1, and ITGB3), whereas most
down-regulated genes were implicated in the cell cycle (KIF11,
CDC2, E2F7, CCNA2, CDKAP2, KIF4A, BUB1, CLSPN, CCNB3,
andMELK). On a clinical level, at t3, tumors showed a drying surface
and hypopigmentation that were confirmed by histologic finding.
Here again, the top 15 up-regulated genes were predominantly of
monocyte/macrophage origin with additional genes such as CLEC5A
and SIGLEC5, and the top 15 down-regulated genes were mostly
involved in the cycle (CDK2, CDC2, and KIF11) and also in mela-
nogenesis (KIT). At t4, a major loss of tumor volume was observed,
along with depigmentation and lymphocyte infiltration. Gene expres-
sion showed an increase in T/NK cell (TVB1, TRAC, KLRK1, and
CCL5) and immunoglobulin-associated genes (IGHM, IGKV1–5, and
IGLC1). The apoptosis-related gene UBD was strongly up-regulated.
A loss of melanosomal gene expression was observed (SLC24A5,
TYR, SLC45A2, CITED1, SILV, OCA2, and GPR143), explaining
the depigmentation effect.
Microarray Validation
To validate the microarray results, nine immune response–related
genes that were up-regulated over time and six cell cycle–related
genes that showed a decrease over time were selected for qRT-PCR
analysis (Table W2). In addition,MITF andMLANAwere also quan-
tified by qRT-PCR.
The steady augmentation of the immune genes was confirmed by
qRT-PCR. The up-regulation of molecules (TVB1, TRGV9, KLRK1,
and PRF1) characteristic for immune effector cells such as cytotoxic
T cells (CTLs) and NK cells, their signaling molecules (IL15 and
CCL5), and SLC37A2,ATP6V0D2 (anATPasemainly active in vacuoles
of macrophages/osteoclasts), and IGHG1 represented a complex im-
mune response including innate and adaptive components. Interest-
ingly, SCIN, an actin-related gene that was shown to play a role in
tumor cell resistance against CTL pressure [24], was also up-regulated
over time.MLANAwasmostly down-regulated (∼27-fold) at t4, whereas
T-cell response genes were expressed at the highest. MITF-M already
showed a decrease in expression (∼4-fold) at t3, whereas at t4, it was
down-regulated up to 80-fold. Furthermore, we validated six genes as-
sociated with an early retardation of the cell cycle, namely, CCNB1,
CDC2, BUB1B, BIRC5, KIF11, and CKAP2. All genes were at least
twofold down-regulated from t2 onward, except BIRC5.
Discussion
We used the MeLiMmodel to conduct the first genome-wide time-
dependent gene expression profiling to analyze molecular mechanisms
involved in spontaneous melanoma regression. A total of 1411 genes
were significantly regulated during melanoma regression. Functional
analysis by IPA revealed highly significant functional gene classes
namely Cell Death, Cell Cycle, Cellular Movement, Immune Response,
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Hair and Skin Development and Function, and DNA Replication, Re-
combination, and Repair that changed over time.
The reference of our gene expression profiling study consisted of
growing tumors excised at t0 (d + 8) that showed extensive dermal
invasion. The expression profiles of the reference (t0) could therefore
not be exploited. However, we showed previously by subtractive sup-
pression hybridization (SSH) that genes up-regulated at t0 were
connected to a highly proliferative gene signature [13]. Expression
Figure 3. Regulation of immune response–related genes during melanoma progression and regression. Fold changes relative to t0: (A)
monocyte/macrophage–related gene signature; (B) T-cell– and NK-cell–related gene signature; (C) immunoglobulin signature; (D) cyto-
kine/chemokine and their receptors.
Figure 2. Functional analysis of clustered genes regulated over time (IPA). (A) Functional gene classes changing over time. Y-axis in-
dicates the significance (−log P value) of the functional association that is dependent of the number of genes in a class as well as
biologic relevance. Furthermore, the number of genes up- and down-regulated as well as their FC of regulation is noted. (B) Most sig-
nificant gene network detected at t2 by IPA. A total of 25 focus genes were identified and mapped to top IPA functional classes such as
cancer, cell cycle, and cellular compromise (significance: score, 44). A score of three indicates that there is a 1/1000 (score = −log10(P
value)) chance that the focus genes are assigned to a network randomly. The maximal number of focus genes per network is set to be
35 by IPA network algorithm. Whereas green gene symbols refer to down-regulation, red gene symbols refer to up-regulation. The color
intensity is correlated with FC. Uncolored gene symbols were not identified in this study but suggested to be in functional proximity by
IPA network algorithm. Straight lines suggest direct gene to gene interactions whereas dashed lines indirect ones.
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profiles at t1 were not very different from t0, indicating an ongoing
growth phase. Nevertheless, immunoglobulin-related genes (IGHM
and IGLC1) and fibronectin (FN1), which is involved in tumor in-
vasion, were up-regulated at t1.
Interestingly, we observed an early down-regulation of genes in-
volved in Cell Cycle and DNA Replication, Recombination, and Repair
starting at t1 and most remarkably at t2 and t3, suggesting a slowdown
of the cell cycle and therefore reduced proliferative capacity of mela-
noma cells. This could be the first indicator of spontaneous regression.
At least 11 of the top 15 down-regulated genes at t2 were connected
with cell cycle and DNA repair mechanisms. The most significant
gene network, detected by IPA analysis, was mainly composed of genes
(86%) involved in cell cycle mechanisms. Cyclins such as CCNB1 and
CCNA2, cyclin-dependent kinases such as CDC2 and CDC6, and
spindle and chromosome structure-related proteins such as kinesins
(KIF11 and KIF2C), NEK2, MELK, TOP2A, BUB1, and BIRC5,
playing roles in chromosome segregation and cell cycle checkpoint
control, showed the most drastic down-regulation during spontaneous
regression suggesting cell cycle retardation. CCNB1 and CDC2 form
the maturation-promoting factor (MPF) complex and thereby regulate
mitosis; CKAP2 and KIF11 are spindle-associated molecules critical for
mitosis, suggesting a mitotic arrest of melanoma cells at early regres-
sion. BUB1B codes for a kinase involved in spindle checkpoint func-
tion, and BIRC5 acts as an inhibitor of apoptosis lately shown to be
also recognized as an antigen by CD8+ T cells in multiple-myeloma
patients [25]. We confirmed the down-regulation of six cell cycle genes
(KIF11, CCNB1, CDC2, BUB1B, BIRC5, and CKAP2) by qRT-PCR.
This is the first time that the expression of kinesin family member 11
(KIF11) is described in melanoma. KIF11 encodes for a motor protein
that is involved in spindle formation, and it has become a promising
target for antimitotic cancer therapy [26]. Most cell cycle genes that we
found down-regulated were involved in mitosis (∼70%).
Most of these genes were recently reported to be related to aggres-
siveness of human melanoma but were regulated in the opposite way,
suggesting that the reversal of a metastatic signature could lead to tumor
regression [14,16,17]. Three genes (KPNA2, CDC2, and KIF11),
which were associated with higher metastatic potential of human
melanoma tissue, already showed a trend of down-regulation at t1,
although no signs of regression were detected [16]. Even gene signa-
tures of melanoma cell lines showed common but inversely expressed
genes (NUSAP1, BIRC5, GINS1, NCAP2, MELK, and HELLS) that
were cell cycle–related [17]. At t3, when regression signs were already
Figure 4. Clinical, histologic, immunohistologic, and gene expression analysis of spontaneous melanoma development and regression. (A)
Kinetics of clinical and histologic progression and regression of MeLiM melanomas. (B) Immunohistologic evaluation of tumors used for
microarray analysis, characterizing monocytes by SWC3, T cells by CD3, and CTLs by CD3 and CD8. (C) Gene expression analysis. t0 was
used as transcriptomic reference. Top 15 up-regulated and top 15 down-regulated genes per time point compared to t0 are demonstrated.
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established, we identified 10 genes down-regulated (PLP1, EDNRB,
CITED1, TFAP2A, RAB38, TYR, MITF, GPR143, GPM6B, and
GPRC5B), while in humans, the up-regulation of these 10 genes
was associated with a highly proliferative and weakly metastatic po-
tential in primary melanoma cell lines [14].
The use of melanoma tissue in expression studies is often stated as a
drawback because normal or reactive tissue constituents (e.g., vessels,
inflammatory cells, normal epithelium) are interpreted as “contami-
nants” [27]. In our case, the interest was to obtain a global understand-
ing of regression mechanisms related to melanoma cells and their
surrounding, because the tumor microenvironment has recently been
found to influence the progression of cancer by inducing phenotypic
changes in cancer cells [28] and is therefore also very likely to be in-
volved in regression [29].
To address questions of expression specificity, we laser-microdissected
tumor regions of homogenous melanoma cells at early time points such
as t0, t1, and t2 and confirmed the early down-regulation of CCNB1
and CDC2 by qRT-PCR, indicating that the cell cycle retardation
phenomenon is mainly linked to melanoma cells. Furthermore, im-
munohistochemical analysis identified melanoma cells positive for
KIF11, CCNB1, and BIRC5 protein expression (data not shown).
The question, why early cell cycle retardation occurs, needs fur-
ther investigation.
Possible mechanisms include senescence, which is defined as the ir-
reversible loss of division capacity, but melanoma senescence–associated
genes such as HDAC1, p16INK4a, and p21 were not regulated, suggest-
ing that an induction of senescence is not very likely to be involved in
the regression process. Terminal differentiation of melanoma cells into
pigment-laden macrophages was also suggested as an early event in
spontaneously regressing melanoma using the Sinclair swine, another
spontaneously regressing melanoma model [30]. Indeed, differentiation
occurs in human malignant melanoma through diverse pathways as re-
viewed by Banerjee and Eyden [31]. However, genes frequently in-
volved in human melanoma differentiation, such as NCAM and SYP,
were not regulated. Induction of melanoma regression could either
be initiated by the tumor cells itself or is a consequence of extrinsic
mechanisms such as an antitumor immune response or a beneficial in-
teraction of both.
Recent studies demonstrated that spontaneous regression is medi-
ated by infiltration of leukocytes mostly of innate immunity [32,33].
Spontaneous melanoma regression inMeLiM is highly correlated with
an increase of immune response–related genes. Apparently, the tumor
does not succeed in escaping the immune attack, as it is mostly the
case in human melanoma [34]. In our model, we detected a strong
up-regulation of monocyte/macrophage–related genes from t2 to
t3, which corresponded with the appearance of histiocyte-like cell in-
filtrates on a histologic level. Tumor-infiltrating macrophages were
shown to play a dual role in carcinogenesis because they can enhance
and inhibit tumor growth depending on their activation and secretion
of effector molecules [35]. Molecules associated with an inhibitory
effect, such as IL-10, IL-13, IL-4, and TGFB1, were present on our
microarray but did not show significant regulation. Characteristics of
Figure 5. Immunohistochemical and FACS analysis of tumor-infiltrating lymphocytes (TILs) at t4. (A) Histologic and immunohistologic
analyses of melanoma sections at t4 show extensive lymphocyte infiltrate. Lymphocytes were CD3-positive (Alexa Fluor 555) and/or
CD8-positive (FITC). (B) As analyzed by flow cytometry, isolated TILs at t4 were mainly expressing CD8 (∼42.8%, n = 8, SD = 8.4%).
CD4+ TILs (22.2%, n = 8, SD = 3.1%) were also present.
Neoplasia Vol. 10, No. 7, 2008 Gene Expression Profiling in Porcine Melanoma Regression Rambow et al. 723
these cells include hyperpigmentation, aneuploidy, increased size, and
irregular borders. Phenotypically similar cells in melanoma have been
associated with osteoclast-like giant cells [36], melanophages [37], and
macrophage–melanoma fusion hybrids [38]. In fact, overexpression of
many genes in our case were characteristic but not exclusive for osteo-
clasts such as PU.1, SCIN, ITGB3, ATP6V0D2, and ACP5 [39],
whereas high expression of ACP5 in mouse macrophages was shown
to enhance cytotoxicity by increased ROS and superoxide production
[40]. In the spontaneous regression/complete resistance (SR/CR)
mouse model [32], macrophages were demonstrated to induce tumor
apoptosis by cell contact–dependent secretion of ROS and serine pro-
teases. Although antibodies against tumors were produced in SR/CR
mice, they were not required for killing, suggesting that antibody-
dependent cellular cytotoxicity is not an effector mechanism in
this model. Regression in MeLiM is accompanied by an early up-
regulation of immunoglobulins (kappa and lambda light chain and
heavy chain loci) proposing also a humoral response. We detected a
major increase in IGHM levels between t3 and t4, although at t1,
IGHM was already 10-fold up-regulated compared to t0. One might
suggest that a humoral response could be the initiator of melanoma
regression, but qRT-PCR analysis revealed equal levels of IGHM ex-
pression in melanoma tissue at t1 and healthy skin (data not shown).
Furthermore, a stronger up-regulation of IgM levels would be expected
if it is the initiating mechanism, because normal pigs already show
stable IgM serum levels throughout their first 3 weeks of life and are
therefore fully armed to fight the tumor at t1 [41].
Spontaneous regression of melanoma in humans is rare and hard to
study; however, larger numbers of CD4+ T cells were found in tumor
infiltrates besides high percentages of Langerhans cells, macrophages,
and other major histocompatibility complex II–expressing cells [42].
We detected a significant up-regulation of different T-cell receptor
chains at a late stage of regression (t4), as well as T-cell–associated
cytokines (CCL5 and IL15), effector molecules such as granzyme B, per-
forin (verified by qRT-PCR), and theNKG2D receptor. Flow cytometry
and immunohistochemical analysis of MeLiM–TILs around t4 showed
higher percentages of CD8+ than CD4+ T cells, suggesting a predomi-
nant CTL response in our case. γ/δT cells as well as CD4+CD8+ T cells
and CD16+CD8+ NK cells did not seem to play a role in regression be-
cause they were almost not detectable in tumor infiltrates compared to
peripheral blood mononuclear cells (data not shown).
MeLiM show signs of autoimmune reactions such as localized or
systemic vitiligo-like depigmentation. This phenomenon could be
explained by cross-antigenicity that occurs between melanoma and
normal melanocytes. The presence of vitiligo in melanoma patients
seems to improve the prognosis of melanoma by means of effective
immunity against the tumor [43]. Autoantibodies isolated from vit-
iligo patients were shown to trigger apoptosis in melanocyte cultures
[44]. Furthermore, antimelanoma antibodies were isolated from
Sinclair swine, recognizing antigens expressed on the surface of nor-
mal melanocytes [45].
CD8+ T cells isolated from peripheral blood of vitiligo patients
were also shown to frequently recognize the melanosomal protein
MLANA and kill human leukocyte antigen–matched melanoma cells
[46], playing therefore a role in the depigmentation process. We
confirmed the down-regulation of MLANA expression during spon-
taneous regression by qRT-PCR analysis. The expression of addi-
tional genes involved in melanogenesis, such as SILV, SLC24A5,
OCA2, CITED1, and TYR, was dramatically down-regulated at t4,
which confirmed a major loss of melanoma cells at the end of regres-
sion. Tumors at t0 showed severe hyperpigmentation, probably a con-
sequence of genetically induced abnormal melanogenesis. High levels
of melanin have been reported to be protective against ROS, includ-
ing OH, O2−, and H2O2 [47], whereas accumulation of melanin
intermediates, produced in the absence of tyrosinase, TYRP1, and
DCT, is cytotoxic [48]. Hence, one may hypothesize that high levels
of melanin in our model could also mediate protective effects against
macrophage produced ROS. Scavenging free radicals could be a
reason for a change in melanin confirmation and subsequent change
in color. At the same time, overexpression of genes involved in the
melanosomal pathway might result in increased immunogenicity be-
cause more melanoma antigens would be presented on the surface
that could be recognized by immune cells [49]. A main immune es-
cape mechanism such as the down-regulation of tumor associated
antigens would be in this case impaired.
The early detected monocyte/macrophage–like signature might
represent the first attempt of the immune response to fight highly
immunogenic melanoma cells, whereas mediated cytotoxicity might
be buffered to some extent by the elevated melanin content. Proper
antigen presentation, as suggested by the presence of major histo-
compatibility complex II molecule CD74 and costimulatory mole-
cule CD86, seems to lead to the activation of CD8+ cytotoxic
effector T cells. The major down-regulation of melanoma antigens
at t4 is coherently accompanied by the up-regulation of T-cell re-
sponse genes. One might expect the detection of a distinct apoptotic
gene signature characteristic for T cell–mediated cytotoxicity includ-
ing genes such as FAS/FASL, caspase 10, and caspase 3. In our case,
apoptosis-related genes were associated with both intrinsic (TP53l11
and BIM) and extrinsic (TNFSF12 and GZMB) death signals lacking
a distinct classification. A possible explanation could be that our
chosen time points for microarray hybridization missed the molecu-
lar detection of the ongoing apoptotic process because programmed
cell death is a rather rapid process. We oriented our choice by con-
sidering major histologic changes such as first signs of regression.
Other apoptotic genes such as CLU, ELMO1, PLEKHF1, and THY1
were detected along with a strong increase of ubiquitin D expression
at t4. Clusterin was maximally up-regulated at t3 (∼12-fold) suggest-
ing a role in early regression, as we have shown and confirmed earlier
by SSH and qRT-PCR [13]. CLU codes for a glycoprotein whose
nuclear isoform seems proapoptotic, and its secretory form antiapop-
totic [50]. CLU was shown not to be expressed by normal melano-
cytes, whereas 30% of primary desmoplastic melanoma and only
13.5% of metastatic tumors were CLU-positive [51]. Future investi-
gations include in vitro experiments to answer questions of cytotoxic
key mechanisms and adoptive transfer of melanoma cells in mice
(beige mice) with functionally defective monocytes, especially phago-
cytes and NK cells [52,53].
In summary, our time-dependent gene expression profiling study of
spontaneously developing and regressing swine melanoma has identi-
fied several significant gene signatures. For the first time, expression
profiles for complete melanoma regression were identified, harboring
potential targets for either chemotherapy (down-regulation of a mi-
totic cell cycle gene signature) or immunotherapy (up-regulation of
a complex immune response signature).
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Figure W1. IPA canonical pathway analysis.
